Anti-tRNA synthetase inflammatory myopathy antibodies
Evidence-based neurology checklist on anti-trna synthetase inflammatory myopathy antibodies: Anti-Jo1 (histidyl): features Severe weakness Arthritis Association with cancer Responsive to Rituximab Anti-OJ (isoleucyl): features Anti-PL7 (threonyl): features Anti-PL12 (alanyl): features Other…
Anti-Jo1 (histidyl): features
- Severe weakness
- Arthritis
- Association with cancer
- Responsive to Rituximab
Anti-OJ (isoleucyl): features
Anti-PL7 (threonyl): features
Anti-PL12 (alanyl): features
Other anti-tRNA synthetase antibodies
References
- Rietveld A, Lim J, de Visser M, et al. Autoantibody testing in idiopathic inflammatory myopathies. Pract Neurol 2019; pii: practneurol-2017-001742 (Epub ahead of print).
- Stuhlmüller B, Schneider U, González-González JB, Feist E. Disease specific autoantibodies in idiopathic inflammatory myopathies. Front Neurol 2019; 10:438.
- Yamasaki Y, Yamada H, Nozaki T, et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 2006; 54:2004-2009.
- Matsushita T, Hasegawa M, Fujimoto M, et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol 2007; 34:1012-1018.
